NCT00623636View on ClinicalTrials.gov

Phase 3 Study of MAP0004 in Adult Migraineurs

PHASE3CompletedINTERVENTIONAL
Enrollment

902

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions
Migraine Disorders
Interventions
DRUG

MAP0004

MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.

DRUG

Placebo

Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.

Trial Locations (1)

98104

Swedish Pain and Headache Clinic, Seattle

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY

NCT00623636 - Phase 3 Study of MAP0004 in Adult Migraineurs | Biotech Hunter | Biotech Hunter